Strauss David, Kaplunov Briana, Kutikov Alexander, Geynisman Daniel M, Lau Kwan, Smaldone Marc
Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA.
Department of Medical Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, USA.
Urol Case Rep. 2023 Apr 17;48:102399. doi: 10.1016/j.eucr.2023.102399. eCollection 2023 May.
Multimodal immunosuppression is the backbone of modern solid organ transplantation. However, immunosuppression itself is an independent risk factor for post-transplant malignancy. Although skin malignancy is the most common post-transplant malignancy, genitourinary cancers are also described. Dose reduction or cessation of immunosuppression has a beneficial role in the management of transplant patients with concomitant malignancy, but only limited data exist with respect to bladder cancer (BCa). We describe a patient who developed metastatic muscle invasive bladder cancer (MIBC) after diseased donor kidney transplant (DDKT) who was successfully managed with dose reduction and elimination of an immunosuppression regimen.
多模式免疫抑制是现代实体器官移植的支柱。然而，免疫抑制本身是移植后发生恶性肿瘤的独立危险因素。虽然皮肤恶性肿瘤是移植后最常见的恶性肿瘤，但泌尿生殖系统癌症也有相关报道。减少免疫抑制剂量或停用免疫抑制在合并恶性肿瘤的移植患者管理中具有有益作用，但关于膀胱癌（BCa）的数据有限。我们描述了一名在接受患病供体肾移植（DDKT）后发生转移性肌肉浸润性膀胱癌（MIBC）的患者，该患者通过减少免疫抑制剂量并停用免疫抑制方案成功得到治疗。
